[BRAF和MEK抑制剂治疗恶性黑色素瘤的最新进展] - Suppr

Suppr

超能文献

[Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].

作者信息

Gutzmer Ralf

出版信息

J Dtsch Dermatol Ges. 2015 May;13(5):485-7. doi: 10.1111/ddg.12692.

DOI:10.1111/ddg.12692

PMID:25918105

Abstract

摘要

相似文献

[Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].

J Dtsch Dermatol Ges. 2015 May;13(5):485-7. doi: 10.1111/ddg.12692.

From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment.

Future Oncol. 2013 Jan;9(1):5-8. doi: 10.2217/fon.12.169.

[BRAF inhibitor and MEK inhibitor].

Gan To Kagaku Ryoho. 2015 Apr;42(4):428-33.

Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare.

Eur J Cancer. 2017 Sep;82:25-26. doi: 10.1016/j.ejca.2017.05.039. Epub 2017 Jun 21.

A new standard of care for metastatic melanoma?

Lancet Oncol. 2015 Jan;16(1):e8. doi: 10.1016/S1470-2045(14)71138-6. Epub 2014 Nov 21.

Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: experience from an Italian skin cancer unit.

Future Oncol. 2021 Mar;17(7):759-761. doi: 10.2217/fon-2020-0997. Epub 2021 Feb 3.

Targeted Therapy for Melanoma.

Cancer Treat Res. 2016;167:251-62. doi: 10.1007/978-3-319-22539-5_10.

Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.

Oncology. 2017;93(3):164-176. doi: 10.1159/000475715. Epub 2017 Jun 10.

Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials.

Oncotarget. 2015 Sep 29;6(29):28502-12. doi: 10.18632/oncotarget.4375.

BRAF and MEK inhibition in melanoma.

Expert Opin Drug Saf. 2015 Apr;14(4):559-70. doi: 10.1517/14740338.2015.1011618. Epub 2015 Feb 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].

作者信息

Gutzmer Ralf

出版信息

J Dtsch Dermatol Ges. 2015 May;13(5):485-7. doi: 10.1111/ddg.12692.

DOI:10.1111/ddg.12692

PMID:25918105

Abstract

摘要

相似文献

[Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].

J Dtsch Dermatol Ges. 2015 May;13(5):485-7. doi: 10.1111/ddg.12692.

From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment.

Future Oncol. 2013 Jan;9(1):5-8. doi: 10.2217/fon.12.169.

[BRAF inhibitor and MEK inhibitor].

Gan To Kagaku Ryoho. 2015 Apr;42(4):428-33.

Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare.

Eur J Cancer. 2017 Sep;82:25-26. doi: 10.1016/j.ejca.2017.05.039. Epub 2017 Jun 21.

A new standard of care for metastatic melanoma?

Lancet Oncol. 2015 Jan;16(1):e8. doi: 10.1016/S1470-2045(14)71138-6. Epub 2014 Nov 21.

Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: experience from an Italian skin cancer unit.

Future Oncol. 2021 Mar;17(7):759-761. doi: 10.2217/fon-2020-0997. Epub 2021 Feb 3.

Targeted Therapy for Melanoma.

Cancer Treat Res. 2016;167:251-62. doi: 10.1007/978-3-319-22539-5_10.

Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.

Oncology. 2017;93(3):164-176. doi: 10.1159/000475715. Epub 2017 Jun 10.

Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials.

Oncotarget. 2015 Sep 29;6(29):28502-12. doi: 10.18632/oncotarget.4375.

BRAF and MEK inhibition in melanoma.

Expert Opin Drug Saf. 2015 Apr;14(4):559-70. doi: 10.1517/14740338.2015.1011618. Epub 2015 Feb 4.